biofil chemicals reported a significant surge in revenue for the first quarter of FY27, rising 92% year-on-year to ₹1,235.02 lakh, although net profit plummeted 95% to ₹10.91 lakh. The Board of Directors approved the unaudited financial results on August 11, 2026, attributing the revenue growth primarily to increased trading activities within the Chemical Division. Despite the top-line expansion, profitability contracted as the Pharma Division posted a loss, offsetting gains from the Chemical segment. The company also announced that its manufacturing facility is undergoing renovation to comply with revised Schedule M regulations, with completion expected within three to six months.

The Board meeting held on August 11, 2026, also addressed governance matters, including the continuation of Ashok Kumar Ramawat as a Non-Executive Independent Director upon attaining the age of 75 years, based on recommendations from the Nomination and Remuneration Committee. The Board approved the Board’s Report on Operations and the Corporate Governance Report for the year ended March 31, 2026. Additionally, the company scheduled its 41st Annual General Meeting for September 23, 2026, to be conducted via Video Conferencing or Other Audio-Visual Means.

Financial Performance

Revenue from operations climbed to ₹1,235.02 lakh in Q1FY27, compared to ₹643.26 lakh in the corresponding quarter of the previous year. Total income stood at ₹1,241.28 lakh, down from ₹926.46 lakh in Q1FY26 when adjusted for the massive drop in other income. Other income fell drastically to ₹6.26 lakh from ₹283.20 lakh in the prior year period. Total expenses increased to ₹1,227.87 lakh from ₹650.21 lakh, largely due to higher purchases of stock-in-trade and cost of materials consumed associated with trading volumes.

Segment Analysis

The Chemical Division was the primary driver of revenue growth, contributing ₹921.62 lakh compared to ₹158.51 lakh in Q1FY26. This division generated a segment profit of ₹15.43 lakh. In contrast, the Pharma Division saw revenue decline to ₹313.40 lakh from ₹484.75 lakh and incurred a segment loss of ₹6.41 lakh, widening from a profit of ₹269.74 lakh in the previous year. The divergence highlights a shift in business mix towards trading activities rather than manufactured pharma products during this quarter.

What the Numbers Show

The financial data reveals a structural shift in Biofil Chemicals’ operations during Q1FY27. While revenue nearly doubled, the nature of this growth is predominantly transactional, evidenced by the sharp rise in 'Purchases of stock-in-trade' (₹311.58 lakh vs ₹974.06 lakh prior year) and 'Cost of materials consumed' (₹948.18 lakh vs ₹117.14 lakh). The collapse in 'Other Income' from ₹283.20 lakh to ₹6.26 lakh suggests the prior year’s profitability was partly supported by non-operational gains. Furthermore, the Pharma Division’s transition from a high-margin profit center to a loss-making unit indicates ongoing operational challenges or strategic pausing, likely linked to the mentioned manufacturing facility upgrades. Investors should monitor whether the upcoming completion of Schedule M compliance will restore manufacturing-led margins in subsequent quarters.

Biofil Chemicals and Pharmaceuticals Limited reported a net profit of ₹278.60 crore for the financial year ended March 31, 2026, a significant increase from ₹55.78 crore in the previous year. The company's revenue from operations for FY26 stood at ₹2839.52 crore, down from ₹3340.22 crore in FY25. The Board of Directors approved the audited financial results for the fourth quarter and the financial year ended March 31, 2026, in a meeting held on May 30, 2026.

The statutory auditors, Maheshwari & Gupta, Chartered Accountants, issued an unmodified opinion on the standalone financial results. The audit was conducted in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. The company confirmed that the statement on impact of audit qualifications is not required as the auditors did not express any modified opinion or reservation.

For the quarter ended March 31, 2026, the company reported a net profit of ₹21.22 crore on a revenue from operations of ₹756.56 crore. Total income for the quarter was ₹767.41 crore, with total expenses amounting to ₹720.53 crore. The basic and diluted earnings per share for the quarter were ₹0.13, while for the full year, they stood at ₹1.71.

Financial Performance

The following table summarizes the key financial figures for the quarter and year ended March 31, 2026:

Segment Reporting

The company operates through two primary business segments: Pharma Division and Chemical Division. For the year ended March 31, 2026, the Pharma Division reported a revenue of ₹1,896.33 crore, while the Chemical Division contributed ₹943.19 crore. The Pharma Division recorded a segment profit before tax of ₹235.90 crore, whereas the Chemical Division reported a profit of ₹94.69 crore.

Operational Updates

The company noted that manufacturing operations were partially disrupted during the year due to renovation and upgradation work at the factory, necessitated by a revision in Schedule M of the Drug & Cosmetics Rules. This disruption resulted in a decline in turnover compared to the previous year. Additionally, the net profit for the year increased due to the disposal of an undertaking situated at Sanwer Road Industrial Area, Indore, to Formo Plast Private Limited.

The company submitted newspaper clippings of the publication of these audited financial results to the stock exchanges on June 1, 2026. The results were published in Free Press Mumbai & Indore (English) and Choutha Sansar (Hindi) on May 31, 2026.